How Device Firms Can Play the Pricing Game to Improve Franchise Value
Executive Summary
Price erosion--and its significant impact on profitability--has been a way of life for most medical device companies for years. But changes in the markeplace, particularly in GPO contracting strategies, may open the door to a re-thinking of the inevitability of price discounts. For many medical device and supply companies, the potential impact from raising the game on pricing performace is significant and available now. It can add 15-30% or more in franchise value and be a source of sustained competitive advantage.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.